** Shares of medical device maker Tandem Diabetes Care TNDM.O rise 3.5% to $33.8
** Company says U.S. FDA has granted clearance for its automated insulin delivery device, Control-IQ+, for patients with type 2 diabetes
** The device is already approved by the FDA among patients with type 1 diabetes
** TNDM expects the device to be available for new and existing customers in the U.S. by March of this year
** Stock has risen 13.1% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.